Lundbeck's Lu AF28996 Shows Early Promise in Advanced Parkinson's Trial
Event summary
- Lundbeck presented Phase Ib data for Lu AF28996, showing improved motor fluctuations and reduced dyskinesia in advanced Parkinson's patients.
- The open-label trial reported mild adverse events, with most participants experiencing increased Good ON-time and reduced OFF-time.
- Lundbeck has initiated the Phase II DARE2 trial, with the first patient randomized and recruitment ongoing in multiple countries.
- Lu AF28996 is an investigational oral prodrug targeting D1-like/D2-like dopamine receptors, aiming to enhance dopaminergic signaling.
The big picture
Lundbeck's Phase Ib results for Lu AF28996 highlight the ongoing need for better treatments for advanced Parkinson's disease, where motor fluctuations and dyskinesia remain significant challenges. The transition to a Phase II trial marks a critical step in validating the drug's potential, as the global prevalence of Parkinson's disease is projected to more than double by 2050. Lundbeck's focus on brain health innovation positions it to capitalize on the growing demand for effective, non-invasive therapies in neurology.
What we're watching
- Clinical Efficacy
- Whether Lu AF28996 can sustain observed improvements in motor fluctuations and dyskinesia in the larger, placebo-controlled Phase II trial.
- Regulatory Pathway
- The pace at which Lundbeck can advance Lu AF28996 through clinical trials and potential regulatory approvals.
- Market Potential
- How Lu AF28996's non-invasive approach could position it against existing treatments for advanced Parkinson's disease.